← Leaderboards
Susan M Catalano
Cognition Therapeutics, Inc.
$36,630,926
Attributed
$52,986,812
Total exposure
11
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $24.9M · FY2010–20$25M$18.8M$12.5M$6.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$52,986,812 · 11
By mechanism
R01$35,328,949 · 2
RF1$12,144,383 · 4
R44$3,652,204 · 2
U01$1,520,864 · 1
R43$340,412 · 2
Top collaborators
- Paul S. Aisen1 shared
- Christopher H Van Dyck1 shared
Most similar at Cognition Therapeutics, Inc.
Same institution · by research overlap
- Christopher H Van Dyck$43,230,259
- Anthony O Caggiano$51,394,003
- Paul S. Aisen$209,920,520
- Nicholas John Izzo$4,437,830
- Mary E Hamby$9,832,688
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposBrainNeuronsPharmaceutical PreparationsProteinsCognitionAmyloid Beta-ProteinS DiseaseAbeta OligomerReceptorSynapsesPreventDesignClinical TrialsMouse ModelDrug CandidateFundingOralPlasmaDoseSmall MoleculeIn VitroMemoryReceptor Binding
Grant awards (23)
Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months$24,533,829
R01 · FY2020 · AG · contact PI
A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Subjects with Mild to Moderate Alzheimer's Disease$324,481
RF1 · FY2020 · AG · contact PI
A Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Phase II Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild to Moderate Alzheimer's Disease$5,735,586
R01 · FY2019 · AG · contact PI
Structural variants of Abeta oligomer displacing small molecules$730,417
R44 · FY2019 · AG · contact PI
A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Subjects with Mild to Moderate Alzheimer's Disease$340,552
RF1 · FY2019 · AG · contact PI
A Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Phase II Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild to Moderate Alzheimer's Disease$5,059,534
R01 · FY2018 · AG · contact PI
Target Engagement Biomarkers for Alzheimer's Therapeutics$746,126
R44 · FY2018 · AG · contact PI
Structural variants of Abeta oligomer displacing small molecules$734,351
R44 · FY2018 · AG · contact PI
Target Engagement Biomarkers for Alzheimer's Therapeutics$250,000
R44 · FY2018 · AG · contact PI
A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Subjects with Mild to Moderate Alzheimer's Disease$4,130,741
RF1 · FY2017 · AG · contact PI
A Pilot CSF Catheter Study to Evaluate the Effect of CT1812 Treatment on Aβ Oligomer Clearance into CSF in Subjects with Mild to Moderate Alzheimerʼs Disease$2,527,271
RF1 · FY2017 · AG · contact PI
Target Engagement Biomarkers for Alzheimer's Therapeutics$745,159
R44 · FY2017 · AG · contact PI
Structural variants of Abeta oligomer displacing small molecules$224,147
R44 · FY2017 · AG · contact PI
Lead Optimization of receptor antagonist CT0093 for disease-modifying Alzheimer's$88,972
U01 · FY2017 · AG · contact PI
Phase 1b first-in-patient safety trial for CT1812, a novel Alzheimerâs synaptic protection therapeutic$2,410,669
RF1 · FY2016 · AG · contact PI
Phase 1 safety trial for CT1812, a novel small molecule therapeutic targeting a synaptic receptor for Abeta oligomers$2,410,669
RF1 · FY2016 · AG · contact PI
Target Engagement Biomarkers for Alzheimer's Therapeutics$222,004
R44 · FY2016 · AG · contact PI
Lead Optimization of receptor antagonist CT0093 for disease-modifying Alzheimer's$147,082
U01 · FY2016 · AG · contact PI
Lead Optimization of receptor antagonist CT0093 for disease-modifying Alzheimer's$100,000
U01 · FY2016 · AG · contact PI
Lead Optimization of receptor antagonist CT0093 for disease-modifying Alzheimer's$484,895
U01 · FY2015 · AG · contact PI
Lead Optimization of receptor antagonist CT0093 for disease-modifying Alzheimer's$699,915
U01 · FY2014 · AG · contact PI
Pharmacokinetic and pharmacodynamic optimization of soluble Abeta oligomer recept$142,036
R43 · FY2012 · NS · contact PI
Small Molecule Oligomer Formation Inhibitors$198,376
R43 · FY2010 · AG · contact PI